Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

266.95INR
3:47pm IST
Change (% chg)

Rs-2.20 (-0.82%)
Prev Close
Rs269.15
Open
Rs269.10
Day's High
Rs272.85
Day's Low
Rs264.60
Volume
1,445,582
Avg. Vol
1,403,453
52-wk High
Rs352.60
52-wk Low
Rs206.50

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says Zydus Gets Positive Results From Clinical Trial Of Saroglitazar Magnesium In NAFLD And NASH
Wednesday, 2 Oct 2019 

Oct 2 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD - ZYDUS ANNOUNCES POSITIVE RESULTS FROM EVIDENCES IV PHASE 2 CLINICAL TRIAL OF SAROGLITAZAR MAGNESIUM IN NAFLD AND NASH.  Full Article

Cadila Healthcare Unit Gets USFDA Nod For Clobetasol Propionate Lotion
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - Cadila Healthcare Ltd ::RECEIVES FINAL APPROVAL FROM USFDA FOR CLOBETASOL PROPIONATE LOTION..DRUG WILL BE MANUFACTUREDAT THEGROUP'S TOPICAL MANUFACTURINGFACILITY ATAHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Final Nod For Ranolazine Extended-Release Tablets
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR RANOLAZINE EXTENDED-RELEASE TABLETS.PRODUCT WILL BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT BADDI.  Full Article

India's Cadila Says Zydus' Nesher Pharma Gets Final U.S. FDA Nod For ADHD Treatment
Friday, 19 Jul 2019 

July 19 (Reuters) - Cadila Healthcare Ltd ::ZYDUS' NESHER PHARMACEUTICALS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR ADHD TREATMENT.  Full Article

Cadila Healthcare Zydus Gets Final Approval From USFDA For Misoprostol Tablets
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM THE USFDA FOR MISOPROSTOL TABLETS".  Full Article

Cadila Healthcare Unit Zydus Gets FDA Nod For Chlorthalidone Tablets
Monday, 13 May 2019 

May 13 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR CHLORTHALIDONE TABLETS USP.TABLETS WILL BE MANUFACTURED AT THE GROUP'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Final U.S. FDA Approval For Acetazolamide Injection
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR ACETAZOLAMIDE FOR INJECTION.  Full Article

Cadila Healthcare Says Zydus Gets Tentative USFDA Nod For Lacosamide Tablets
Monday, 8 Apr 2019 

April 8 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR LACOSAMIDE TABLETS.DRUG WILL BE MANUFACTURED AT THE GROUP'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD .LACOSAMIDE IS AN ANTICONVULSANT OR ANTIEPILEPTIC DRUG, USED TO PREVENT AND CONTROL SEIZURES.  Full Article

Cadila Healthcare Says U.S FDA Inspects Formulations Manufacturing Facility At Pharmez
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Cadila Healthcare Ltd ::U.S FDA INSPECTED CO‘S FORMULATIONS MANUFACTURING FACILITY LOCATED AT PHARMEZ, AHMEDABAD.INSPECTION CONCLUDED WITH ONE OBSERVATION.  Full Article

Cadila Healthcare Says Zydus Got USFDA Nod For Mirabegron Extended-Release Tablets
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR MIRABEGRON EXTENDED-RELEASE TABLETS.  Full Article